Cabergoline During PCT: How Elevated Prolactin Delays HPTA Recovery After 19-Nor Steroid Cycles

Cabergoline during PCT is the most overlooked component of post-cycle therapy after Nandrolone and Trenbolone cycles, and neglecting it is one of the primary reasons why HPTA recovery after 19-nor steroids is slower, harder and less complete than after testosterone-only cycles. Elevated prolactin directly suppresses the pulsatile release of GnRH from the hypothalamus, which means LH and FSH cannot recover to the levels required to restart natural testosterone production. Your Nolvadex is blocking oestrogen at the hypothalamus. Your Intex Pharma HCG 5000IU is stimulating the Leydig cells directly. But if prolactin from your Deca or Tren cycle is still elevated, both interventions are working against a suppressed GnRH pulse generator that neither of them can fix. Only Intex Pharma Cabergoline 0.25mg addresses the prolactin component. Available from Intex Pharma UK, this guide explains the full mechanism, provides the specific cabergoline during PCT protocol, and tells you when to stop based on bloodwork.

Why PCT After 19-Nor Steroids Is Harder Than After Testosterone

After a testosterone-only cycle, PCT faces one primary suppressive force: the exogenous androgens have suppressed the HPTA through negative feedback at the hypothalamus and pituitary. When exogenous testosterone clears, the suppressive signal is removed, and the HPTA begins recovering. SERMs (Nolvadex, Clomid) accelerate this by blocking oestrogen’s negative feedback at the hypothalamus, allowing GnRH to resume pulsatile secretion. HCG stimulates the Leydig cells directly while the pituitary’s own LH output is recovering. The system restarts, typically within 4 to 8 weeks for a standard testosterone cycle with proper PCT.

After a 19-nor cycle, PCT faces two suppressive forces simultaneously. The first is the same androgenic suppression from the exogenous compounds. The second is prolactin-mediated GnRH suppression from the progestogenic activity of Nandrolone or Trenbolone. Even after the 19-nor compound has cleared from the bloodstream, prolactin can remain elevated for weeks because the pituitary’s prolactin-secreting lactotroph cells do not instantly return to baseline once the progestogenic stimulus is removed. During this window, elevated prolactin continues to suppress GnRH pulsatility, which means the SERM at the hypothalamus is trying to disinhibit a pulse generator that prolactin is still holding down from a different pathway. The SERM blocks oestrogen’s brake. Prolactin applies its own, separate brake. The result is a GnRH pulse generator that is partially released but not fully functional.

The Mechanism: How Prolactin Suppresses GnRH During PCT

Bouchard et al. (1985) in the Journal of Clinical Endocrinology and Metabolism provided the definitive evidence that hyperprolactinemia produces hypogonadism primarily by interfering with pulsatile GnRH release. The researchers administered pulsatile GnRH to four men with prolactinomas (chronically elevated prolactin) and found that exogenous GnRH pulses completely restored LH pulsatility and normalised testosterone levels, even though prolactin remained elevated. This proved that the pituitary and the testes were capable of responding normally; the problem was upstream, at the GnRH pulse generator in the hypothalamus. Prolactin was suppressing the signal, not the target organs.

For a steroid user entering PCT after a Deca or Tren cycle, this has direct practical consequences. SERMs work by removing oestrogen’s negative feedback at the hypothalamus, which allows the GnRH pulse generator to increase its output. But if prolactin is also suppressing that same pulse generator through a separate pathway (involving kisspeptin neuron inhibition and increased dopaminergic tone in the arcuate nucleus), the SERM can only partially restore GnRH pulsatility. The prolactin brake remains engaged regardless of how much Nolvadex or Clomid you take. This is why users report that PCT after Deca “just doesn’t work as well” compared to PCT after testosterone. The SERM is addressing one suppressive input while a second, prolactin-mediated input remains unaddressed.

Cheung (1983) in Endocrinology further demonstrated that hyperprolactinemia directly inhibits pituitary GnRH receptor upregulation: even when GnRH pulses are present, elevated prolactin reduces the number of GnRH receptors on gonadotroph cells, blunting the LH response. This means prolactin does not only suppress the hypothalamic signal; it also reduces the pituitary’s sensitivity to whatever signal does get through. The suppression operates at two levels simultaneously, making it a particularly effective block on HPTA recovery.

Why Nandrolone Decanoate Is the Worst 19-Nor for PCT Recovery

Among the 19-nor compounds, Intex Pharma Nandrolone Decanoate 300mg presents the most challenging PCT scenario because of two compounding factors. First, the decanoate ester has one of the longest active lives in common use (14 to 21 days), meaning the parent compound continues to exert progestogenic activity for weeks after the last injection. Second, Nandrolone produces the metabolite 19-norandrosterone, which has been detected in urine for months after cessation. While the metabolite’s direct progestogenic contribution is debated, the extended pharmacokinetic tail of Nandrolone Decanoate means that the progestogenic stimulus driving prolactin elevation persists far longer than with shorter-ester 19-nors like NPP or Trenbolone Acetate.

This is why the standard PCT protocol for Nandrolone Decanoate includes a longer clearance window before starting Nolvadex (typically 3 to 4 weeks after the last injection), and why cabergoline during PCT must be continued throughout this window and into the active PCT phase. Stopping cabergoline when you stop injecting Deca means prolactin is unmanaged during the exact period when the decanoate ester is still releasing active Nandrolone. For users running Intex Pharma Testosterone Enanthate 300mg alongside Nandrolone, the testosterone base should also be continued at TRT dose during the clearance window to prevent a complete androgen crash before PCT compounds are started.

The Complete Cabergoline During PCT Protocol After a 19-Nor Cycle

What Happens When You Skip Cabergoline During PCT After Deca

Without cabergoline during PCT, elevated prolactin suppresses GnRH pulsatility throughout the entire recovery window. Nolvadex removes the oestrogen brake but cannot remove the prolactin brake. LH recovery is blunted, FSH recovery is incomplete, and natural testosterone production restarts at a fraction of the rate it would with normalised prolactin. The user experiences a prolonged hypogonadal state: persistent fatigue, flat mood, absent libido, muscle loss and fat gain that extends weeks to months beyond what a properly managed PCT would produce.

Forum wisdom often attributes this prolonged recovery to “Deca being suppressive” as though it is an inherent, unavoidable property of the compound that cannot be mitigated. In reality, much of the prolonged suppression is from residual prolactin elevation that could have been controlled with cabergoline. The compound itself does clear. The decanoate ester is fully metabolised within 4 to 6 weeks. What lingers is the downstream prolactin elevation that was never addressed, continuing to suppress GnRH pulsatility for weeks after the compound has left the body.

Additionally, elevated prolactin during PCT impairs sexual function through dopamine suppression, compounding the hypogonadal state with prolactin-driven erectile dysfunction and loss of libido. The user is simultaneously androgen-deficient (because natural testosterone has not yet restarted) and dopamine-deficient (because prolactin is suppressing dopaminergic activity). This dual deficit produces a quality-of-life crash that is far worse than the hypogonadal state from a testosterone-only PCT, where at least the dopamine pathway is unimpaired. For the full neurochemical explanation of how prolactin destroys libido, see the guide on cabergoline, dopamine and libido on 19-nor steroids.

PCT Bloodwork After a 19-Nor Cycle: What to Test and When

The standard PCT bloodwork panel for a testosterone-only cycle does not include prolactin because prolactin elevation is not a concern after testosterone. After a 19-nor cycle, prolactin must be added to every PCT blood draw. Without it, you are running PCT blind to a suppressive force that may be the primary reason your recovery is stalled.

Draw this panel at weeks 3 to 4 of active Nolvadex use (which is approximately weeks 6 to 8 after the last Nandrolone Decanoate injection). If LH and testosterone are recovering well and prolactin is within range, cabergoline can be tapered and stopped. If LH and testosterone are stalled and prolactin remains elevated, the cabergoline dose should be maintained or increased and the bloodwork repeated in 4 weeks. Never extend Nolvadex beyond 6 to 8 weeks simply because recovery is slow without first checking whether prolactin is the bottleneck. Detailed guidance on prolactin assay selection and macroprolactin screening is available in the prolactin bloodwork on a steroid cycle guide. The full standard PCT protocol is covered in the PCT protocol with HCG and Clomid, and HCG use during the clearance window is explained in the guide on testicular atrophy prevention during steroid cycles.

Cost of Adding Cabergoline During PCT

At the standard 0.25mg twice weekly dosing, one pack of Intex Pharma Cabergoline 0.25mg (10 tablets, £31.00) lasts 5 weeks, covering the clearance window and most of the active PCT phase. The cost of approximately £6.20 per week for cabergoline during PCT is negligible compared to the cost of a failed or prolonged recovery: months of low testosterone symptoms, potential muscle loss, fat gain, mood disruption and the possibility of needing another HCG bridge or extended SERM course to salvage a recovery that proper prolactin management would have supported from the start.

Cabergoline During PCT After 19-Nor Cycles: Frequently Asked Questions